Search results for " evaluation."

showing 10 items of 1351 documents

A/D Conversion Based Measurements: Identification of the Parameters for the Uncertainty Evaluation

2009

A/D conversion based measurementuncertainty evaluationMonte Carlo method.Settore ING-INF/07 - Misure Elettriche E Elettroniche
researchProduct

Clinical evaluation of bempedoic acid for the treatment of hyperlipidaemia.

2021

Bempedoic acid (BA) is a novel first-in-class oral lipid-lowering therapy. BA has been approved by the European Medicinal Agency and Food and Drug Administration and has been commercialised throughout Europe since the end of 2020 as an add-on therapy in patients at high/very-high cardiovascular risk that are not at LDL-C goals with current lipid-lowering treatments. Recently, Italian lipid management experts gathered to discuss several open questions on BA characteristics and BArelated practical clinical issues. The panel permitted collection of its opinions in a ten Q&A format. Aim: The aim of this viewpoint is to discuss and answer several open questions on BA characteristics and BA-r…

ATP citrate lyaseEndocrinology Diabetes and MetabolismMedicine (miscellaneous)HyperlipidemiasPharmacologyLipid-lowering therapyLipid-lowering treatmentMedicineLDL-cholesterolHumansDicarboxylic AcidsHypolipidemic AgentsLdl cholesterolNutrition and DieteticsLipid managementbusiness.industryNovel LDL-C treatment.Fatty AcidsCholesterol LDLBempedoic acidNovel LDL-C treatmentATP citrate lyaseATP citrate lyase; bempedoic acid; LDL-cholesterol; lipid-lowering treatment; novel LDL-C treatmentLipid loweringCardiology and Cardiovascular MedicinebusinessClinical evaluationBempedoic acidNutrition, metabolism, and cardiovascular diseases : NMCD
researchProduct

Localización e identificación de las revistas universitarias para su integración en repositorios institucionales. El caso de la Universitat de Valènc…

2010

[EN] Objectives. Prior to starting up the University of Valencia's (UV) institutional repository, we assessed this institution's real output of periodical publications and drew up the most comprehensive list possible. We also described the visibility of the contents on the Internet. -- Method. We searched the ISSN database and the UV's library catalogue for journals in which the UV is included in the statement of responsibility. -- Results. These two sources did not provide sufficient information, as the University was not listed in all the relevant journals as a publishing entity. In total, 162 journals were found, of which 34.6% are still published. Many have been out of print since the 1…

Acceso abiertocentros universitariosUniversitiesjournalsPublicación científicaScientific PublicationEvaluación de revistasRepositoriesRevistas científicasPeriodical evaluationlcsh:ZUniversitat de Valèncialcsh:Bibliography. Library science. Information resourcesScientific Journalsrevistas científicasOpen Accessevaluación de revistasperiodical evaluationJournalsRepositoriosuniversitiesBiD: Textos Universitaris de Biblioteconomia i Documentació
researchProduct

Prestazioni di accessibilità nei siti archeologici: criteri per la valutazione e miglioramento

2021

Knowledge of the heritage on the part of the visitor is the premise for its conservation and enhancement. In order to appreciate the identity of the site completely, the visitor must enter into an active relationship with the heritage, in a multi-sensorial, safe and comfortable manner. But is this always the case? Archaeological heritage is considered a sort of limited case, in which the general critical conditions of accessibility are emphasized. For this reason, this research, applying a systemic approach, is geared towards evaluating whether, in some of these sites, selected as case-studies, the solutions for accessibility comply with technical and performance features in accordance with…

Accessibility archaeological sites. multicriteria evaluationSettore ICAR/12 - Tecnologia Dell'Architettura
researchProduct

IMPAIRED ALLOCENTRIC SPATIAL MEMORY UNDERLYNG TOPOGRAPHICAL DISORIENTATION

2006

The cognitive processes supporting spatial navigation are considered in the context of a patient (CF) with possible very early Alzheimer's disease who presents with topographical disorientation. Her verbal memory and her recognition memory for unknown buildings, landmarks and outdoor scenes was intact, although she showed an impairment in face processing. By contrast, her navigational ability, quantitatively assessed within a small virtual reality (VR) town, was significantly impaired. Interestingly, she showed a selective impairment in a VR object-location memory test whenever her viewpoint was shifted between presentation and test, but not when tested from the same viewpoint. We suggest t…

Activities of Daily Living/psychology Aged Alzheimer Disease/diagnosis Alzheimer Disease/physiopathology Alzheimer Disease/psychology Animals Disability Evaluation Disease Progression Early Diagnosis Female Hippocampus/pathology Hippocampus/physiopathology Humans Memory/physiology Memory Disorders/diagnosis Memory Disorders/physiopathology Memory Disorders/psychology Middle Aged Models Neurological Neuropsychological Tests Orientation/physiology Space Perception/physiology Verbal Behavior/physiologySettore M-PSI/02 - Psicobiologia E Psicologia Fisiologica
researchProduct

The importance of moral sensitivity when including persons with dementia in qualitative research

2012

Author's version of an article in the journal: Nursing Ethics. Also avaliable from the publisher at: httjp://dx.doi.org/10.1177/0969733012455564 The aim of the article is to show the importance of moral sensitivity when including persons with dementia in research. The article presents and discusses ethical challenges encountered when a total of fifteen persons with dementia from two nursing homes and seven proxies were included in a qualitative study. The examples show that ethical challenges may be unpredictable. As researcher you participate with the informants in their daily life and in the interview situation, and it is not possible to plan all that may happen. A procedural proposal to …

Activities of daily livingInterviewProcess (engineering)research ethicsethical principlesApplied psychologyMoralsInterviews as TopicNursingArgumentActivities of Daily LivingEthics NursingmedicineDementiaEthicsResearch ethicsComputingMilieux_THECOMPUTINGPROFESSIONResearchdementia researchProfessional-Patient RelationsGuidelinemedicine.diseaseNursing HomesNursing Researchmoral sensitivityIssues ethics and legal aspectsNursing Evaluation ResearchVDP::Medisinske Fag: 700::Helsefag: 800::Sykepleievitenskap: 808Practice Guidelines as TopicDementiaPsychologyqualitative researchQualitative researchNursing Ethics
researchProduct

Synthetic indicator of the impact of colorectal cancer screening programmes on incidence rates

2020

ObjectiveThe impact of a screening programme on colorectal cancer (CRC) incidence in its target population depends on several variables, including coverage with invitations, participation rate, positivity rate of the screening test, compliance with an invitation to second-level assessment and endoscopists’ sensitivity. We propose a synthetic indicator that may account for all the variables influencing the potential impact of a screening programme on CRC incidence.DesignWe defined the ‘rate of advanced adenoma on the target population’ (AA-TAP) as the rate of patients who received a diagnosis of advanced adenoma within a screening programme, divided by the programme target population. We com…

AdenomaMaleColorectal cancercolorectal cancerTarget populationcolorectal cancer screeningNOScreening programmeSingle indicatormedicineHumansMass ScreeningNational levelEarly Detection of CancerAgedPotential impactbusiness.industryIncidenceIncidence (epidemiology)GastroenterologyColonoscopycolorectal cancer; colorectal cancer screening; Adenoma; Aged; Colonoscopy; Colorectal Neoplasms; Early Detection of Cancer; Female; Humans; Incidence; Italy; Male; Mass Screening; Middle Aged; Occult Blood; Patient Compliance; Program EvaluationMiddle Agedmedicine.diseaseItalyColorectal cancer screeningOccult BloodPatient ComplianceFemaleColorectal NeoplasmsbusinessProgram EvaluationDemographyGut
researchProduct

Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy

2018

Purpose This multicenter phase II trial evaluated lurbinectedin (PM01183), a selective inhibitor of active transcription of protein-coding genes, in patients with metastatic breast cancer. A unicenter translational substudy assessed potential mechanisms of lurbinectedin resistance. Patients and Methods Two arms were evaluated according to germline BRCA1/2 status: BRCA1/2 mutated (arm A; n = 54) and unselected ( BRCA1/2 wild-type or unknown status; arm B; n = 35). Lurbinectedin starting dose was a 7-mg flat dose and later, 3.5 mg/m2 in arm A. The primary end point was objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST). The translational substudy of resist…

Adult0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyGenes BRCA2Genes BRCA1Phases of clinical researchAntineoplastic AgentsBreast NeoplasmsHeterocyclic Compounds 4 or More RingsMice03 medical and health sciences0302 clinical medicineGermline mutationInternal medicineBiomarkers TumorClinical endpointAnimalsHumansMedicineProgression-free survivalGerm-Line MutationAgedDose-Response Relationship DrugErratabusiness.industryMiddle Agedmedicine.diseaseXenograft Model Antitumor AssaysMetastatic breast cancerProgression-Free SurvivalClinical trial030104 developmental biologyOncologyResponse Evaluation Criteria in Solid Tumors030220 oncology & carcinogenesisBiomarker (medicine)FemalebusinessCarbolinesJournal of Clinical Oncology
researchProduct

Cyclophosphamide plus Epidoxorubicin and 5-Fluorouracil with Folinic Acid as a Novel Treatment in Metastatic Breast Cancer: Preliminary Results of a …

1991

Twenty consecutive patients with advanced breast cancer were treated with a combination of cyclophosphamide 600 mg/m2 i.v. on day 1, epidoxorubicin 75 mg/m2 on day 1, and 5-fluorouracil 375 mg/m2 i.v. with folinic acid 200 mg/m2 i.v. on days 1----3. The overall response rate was 60%, with 10% of patients showing a complete response with a mean duration of 11.1 + months, and 50% of patients a partial response of 7.4 + months. A stabilization of 5.2 + months was obtained in 20% of cases, while 20% of patients progressed. The most frequently observed toxicity was leukopenia, while expected mucosal toxicities were rather mild.

Adult0301 basic medicinemedicine.medical_specialtyCyclophosphamide030106 microbiologyLeucovorinPhases of clinical researchBreast NeoplasmsGastroenterologyMetastasis03 medical and health sciencesFolinic acid0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansPharmacology (medical)Neoplasm MetastasisInfusions IntravenousCyclophosphamideEpirubicinPharmacologyLeukopeniabusiness.industryRemission InductionCancerMiddle Agedmedicine.diseaseMetastatic breast cancerSurgeryInfectious DiseasesOncologyFluorouracil030220 oncology & carcinogenesisDrug EvaluationFemaleFluorouracilmedicine.symptombusinessmedicine.drugJournal of Chemotherapy
researchProduct

Bendamustine with or without rituximab in the treatment of relapsed chronic lymphocytic leukaemia: an Italian retrospective study.

2011

To retrospectively assess the efficacy of bendamustine alone and with rituximab (R-B), 109 patients with relapsed chronic lymphocytic leukaemia (CLL) were enrolled in 24 Italian centres. The median age was 66 years (range 39-85). Forty-three percent of patients had relapsed and 57% were resistant (median previous therapies = 3; range 1-8). Twenty-two patients received bendamustine alone and 87 patients received R-B (median B dosage: 100 mg/m(2) per day, range 90-130 mg/m(2) per day). The overall response rate was 69·6% (complete response 28·6%; partial response 41%), and was significantly higher in patients treated with R-B (P = 0·014) and in those responsive to the previous treatment (P=0·…

AdultAged 80 and overMaleAntineoplastic AgentsMiddle AgedLeukemia Lymphocytic Chronic B-CellAntibodies Monoclonal Murine-DerivedTreatment OutcomeDrug Resistance NeoplasmRecurrenceAntineoplastic Combined Chemotherapy ProtocolsNitrogen Mustard CompoundsBendamustine HydrochlorideDrug EvaluationHumanschronic lymphocytic leukemiaFemaleChronic lymphocytic leukemia; bendamustineBendamustinaEpidemiologic MethodsRituximabAged
researchProduct